Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM
Launch reinforces Johnson & Johnson's position as world leader in contact lenses* – pushing boundaries in optical and material science
JACKSONVILLE, Fla., June 23, 2025 /CNW/ -- Today, Johnson & Johnson, † a global leader in eye health, announced the launch of ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, the first and only daily disposable contact lens for people with both astigmatism and presbyopia. 2 This pioneering contact lens provides patients crisp, clear, stable vision at all distances and in all lighting conditions, along with comfort that lasts all day. 1 The lens is now available in the U.S. and Canada, and the launch of ACUVUE OASYS MAX 1-Day for ASTIGMATISM is expected later this summer.
Experience the full interactive Multichannel News Release here: https://www.multivu.com/johnson-and-johnson/9332851-en-johnson-and-johnson-acuvue-oasys-max-1-day-multifocal-astigmatism
"Building on our legacy of firsts, we are thrilled to launch ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM," said Peter Menziuso, Company Group Chairman, Vision at Johnson & Johnson. ‡"ACUVUE is the world's leading contact lens brand* and with these new products, we now have the first and only complete family of daily-disposable contact lenses. # 2 Clear sight empowers people to live their best lives, and we believe everyone should have the opportunity to achieve it. That's why we focus our innovation on areas with the greatest unmet needs for patients. Today, we are working to fulfill that promise, providing millions of patients with a differentiated ACUVUE experience."
"Finally, patients with both presbyopia and astigmatism can enjoy the freedom and comfort of a daily disposable lens without compromising the quality of their vision," said Dr. Mark Wells, "This new lens was designed to help patients who struggle with multiple vision correction issues, allowing them to experience the comfort and clarity of MAX." 1
Based on extensive studies, 95% of people wearing ACUVUE OASYS MAX 1-DAY MULTIFOCAL for ASTIGMATISM contact lenses reported their vision was clear during their daily activities, § 1 while 87% saw clearly while driving at night. § 1 Additionally, 92% of wearers said their eyes felt comfortable throughout the entire day. ¶ 1
Astigmatism affects about 50% of the population, 3 making it one of the most common vision conditions. It is characterized by imperfections in the curvature of the eye, leading to distorted or blurred vision. Presbyopia, commonly beginning in the early to mid-40s, is the gradual loss of near vision. Traditionally, there has been a gap for people with astigmatism when they begin to experience presbyopia. They've had to make compromises by either switching from daily contact lenses to reusables, or layering reading glasses over their contact lenses.
The ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM contact lens is built with the combination of four proprietary technologies 4 which enable its comfort and visual results: BLINK STABILIZED Design helps the lens stay put, so vision is not distorted or blurry when you blink or move your head. 1,4 PUPIL OPTIMIZED Design helps meet presbyopic vision needs, even as you age and your vision continues to change. 5 TearStable Technology helps keep the lens hydrated, facilitating end of day comfort. †† 1,6,7,8 Finally, the OptiBlue Light Filter provides 60% blue-violet light filtering, the highest in the industry.** ‡‡ 7,8
Later this summer, the ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lens will launch in both the U.S. and Canada, making the ACUVUE OASYS MAX 1-Day Family of lenses the first and only complete daily disposable family of contact lenses on the market. # 2 Both ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM and ACUVUE OASYS MAX 1-Day for ASTIGMATISM are planned to be introduced in additional markets outside North America during 2025 and beyond. To learn more about ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM or to search for an eye care provider, visit https://www.acuvue.com/en-us/oasys-max/.
† About Vision at Johnson & Johnson
Johnson & Johnson has a deep legacy in developing transformational new products that improve the health of patients' eyes. We have a bold ambition: Vision Made Possible – improving sight for more than 40 million people each year. Through cutting-edge innovation, expertise in material and optical science, and advanced technologies, we are revolutionizing the way people see and experience the world. Visit us at clearvisionforyou.com, follow @JNJVision on Twitter, Johnson & Johnson | Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. Johnson & Johnson Vision Care, Inc., a Johnson & Johnson Company.
* Source Euromonitor International Limited; Eyewear 2025 edition; value sales at rsp, all retail channels, 2023 data; "ACUVUE ® family of brands" represents aggregated sales of the following brands: 1-day ACUVUE ®, ACUVUE ® OASYS, ACUVUE ® VITA ®, and ACUVUE ® 2.
‡ Peter Menziuso is an employee of Johnson & Johnson
# Full/complete family consists of sphere, multifocal, toric, and multifocal toric contact lenses
§ Model-adjusted percent estimate
¶ T3B descriptive summaries: n=171
**Filtering of HEV light by contact lenses has not been demonstrated to confer any health benefit to the user, including but not limited to retinal protection, protection from cataract progression, reduced eye strain, improved contrast, improved acuity, reduced glare, improved low light vision, or improved circadian rhythm/sleep cycle. The Eye Care Professional should be consulted for more information.
†† Versus ACUVUE ® OASYS 1-Day, Dailies Total1 ®, My Day ®, Infuse™ and Precision 1 ®.
‡‡ Versus publicly available information for standard daily use contact lenses as of December 2023.
© Johnson & Johnson and its affiliates 2025
2025PP10152
1 JJV Data on file, 2024: Subjective Standalone Claims for ACUVUE® OASYS MAX 1-Day MULTIFOCAL Contact Lenses for ASTIGMATISM
2 JJV Data on File 2025, World's First and Only Daily Disposable Multifocal Toric Contact Lens
3 Young G, Sulley A & Hunt C. Prevalence of Astigmatism in Relation to Soft Contact Lens Fitting; Eye & CL, 2011: 37: 20-25
4 JJV Data on File: Technical Description of ACUVUE ® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM
5 JJV Data on File 2020. ACUVUE OASYS MULTIFOCAL Fit and Performance Claims
6 JJV Data on File 2022. Effect on Tear Film and Evaluation of Visual Artifacts with ACUVUE ® OASYS MAX 1-Day Family.
7 JJV Data on File 2022. JJV Data on File 2022 TearStable™ Technology Definition.
8 JJV Data on File 2022. Material Properties: 1-DAY ACUVUE ® MOIST, 1-DAY ACUVUE ® TruEye ®, ACUVUE ® OASYS 1-Day with HydraLuxe ® Technology and ACUVUE ® OASYS MAX 1-Day with TearStable™ Technology Brand Contact Lenses and other daily disposable contact lens brands.
Important information for contact lens wearers: ACUVUE Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and the lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye doctor immediately. For more information on proper wear, care and safety, talk to your eye care professional, call 1-800-843-2020, or download the Patient Instruction Guides.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the launch of ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM and ACUVUE OASYS MAX 1-Day for ASTIGMATISM contact lenses. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments
Kristyna Muñoz
[email protected]
Investor Contact:
Sandra Easton
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a minute ago
- Cision Canada
NAV CANADA announces appointment of Vice President and Chief Financial Officer Français
OTTAWA, ON, Aug. 21, 2025 /CNW/ - NAV CANADA today announced that Micheline Pion will join NAV CANADA on October 6, 2025 and will assume the position of Vice President and Chief Financial Officer, effective January 8, 2026. Ms. Pion will replace Donna Mathieu who will be retiring as Vice President and Chief Financial Officer on January 7, 2026. Ms. Pion is a highly accomplished executive with over 20 years of progressive experience in finance, strategy, and business transformation. She has held several senior leadership positions across the energy and resources sectors, most recently serving as General Manager, Business Development at Rio Tinto Aluminium, where she supported the development and execution of a global growth strategy. Prior to this, she served as CFO of Evolugen - Brookfield Renewable, where she was responsible for financial oversight, leading strategic financial planning, capital markets, investor relations, regulatory compliance, and risk management. "I am very pleased to welcome Micheline to NAV CANADA. This is a critical leadership role as we continue to strengthen our financial sustainability and deliver value to our stakeholders. Micheline's deep expertise in financial strategy will be invaluable, particularly as we navigate the complexities of our strategic direction and maintain a strong, transparent approach to financial stewardship," said Mark Cooper, President and CEO. NAV CANADA is a private, not-for-profit company, established in 1996, providing air traffic control, airport advisory services, weather briefings and aeronautical information services for more than 18 million square kilometres of Canadian domestic and international airspace. The Company is internationally recognized for its safety record, and technology innovation.
Cision Canada
a minute ago
- Cision Canada
Treaty One Nations Advance Next Phase of Naawi-Oodena Development with New Federal Support
WINNIPEG, TREATY 1 TERRITORY, MB, Aug. 21, 2025 /CNW/ - Treaty One Nations, together with the Government of Canada, are moving forward on the next stage of development of Naawi-Oodena, one of the largest First Nation-led Economic Development Zones in Canadian history. Today, the Honourable Mandy Gull-Masty, Minister of Indigenous Services, visited Naawi-Oodena, a landmark joint urban reserve project located in the heart of Winnipeg. During the tour of Naawi-Oodena, the Minister visited the new Oodena Gas & Convenience Store, which opened in June 2025, to witness first-hand the remarkable progress Treaty One Nations are making in turning its bold economic vision into reality. The future development of Naawi-Oodena includes residential, commercial, education, cultural, sports/recreational, health and community spaces, and will deliver nearly 5,000 housing units on the full site while creating lasting employment opportunities for both First Nation and non-Indigenous Manitobans alike. During her visit, Minister Gull-Masty announced an additional $789,490—bringing the total federal support for infrastructure design to $1 million—to advance planning for Blocks B to E. This funding will support critical site servicing design, surveying, engineering, and cost estimates, ensuring the project can move forward efficiently and sustainably. It will allow Treaty One Nations to build essential infrastructure, including homes, businesses, and educational facilities that will strengthen both the community's economy and overall well-being. This latest funding brings total federal investment in Naawi-Oodena's planning, training, and site development to approximately $5.5 million through Crown-Indigenous Relations and Northern Affairs Canada and Indigenous Services Canada. This includes $3.5 million, which supported the development of Block A, home to Oodena Gas & Convenience—the first business to open on Treaty One's 109 acres of Naawi-Oodena lands. Quotes "This next stage of development at Naawi-Oodena is another milestone in reclaiming and rebuilding our Nations' presence in the heart of Winnipeg. These lands are being transformed into a place of opportunity, growth, and pride for our seven Nations, and we look forward to seeing the vision continue to take shape." Chief Gordon BlueSky Chairperson, Treaty One Nations Chief of Brokenhead Ojibway Nation "This investment shows what's possible when governments support First Nations to lead on our own terms. Naawi-Oodena is a movement toward self-reliance, economic growth, and intergenerational wealth that benefits our Nations and all of Manitoba". Chief E.J. Fontaine President, Treaty One Development Corporation Chief of Sagkeeng First Nation "Congratulations to Treaty One Nations and all seven member First Nations as they begin their latest phase of Naawi-Oodena's development. It has been a pleasure to tour the site and see firsthand the progress built so far and the exciting plans for the future. Treaty One Nations are leading the way in transforming the Canadian economy and contributing to greater prosperity for First Nations communities." The Honourable Mandy Gull-Masty Minister of Indigenous Services "I have watched Naawi-Oodena take shape over the years, and it is incredibly exciting to see the positive economic impacts, which are only going to grow as this Indigenous-led project expands opportunities and drives investment not only for First Nations but also for the entire City of Winnipeg." The Honourable Ben Carr Member of Parliament, Winnipeg South Centre Quick facts Naawi-Oodena is comprised of five parcels of Treaty One Jointly Held urban reserve lands, totaling 109 acres and is located on the former site of the Kapyong Barracks in the Winnipeg South Centre riding. The site is being developed and is jointly owned by the seven First Nations who are signatory to Treaty No. 1, which include: Brokenhead Ojibway Nation, Long Plain First Nation, Peguis First Nation, Roseau River Anishinaabe First Nation, Sagkeeng First Nation, Sandy Bay Ojibway First Nation, and Swan Lake First Nation. Additions to Reserve and Reserve Creation are part of the Government of Canada's overall efforts to help advance reconciliation by facilitating First Nation self-determination, self-governance, and economic development. Treaty No. 1 was signed on August 3, 1871, between the Crown and the Anishinaabe and Swampy Cree peoples at Lower Fort Garry. It covers lands in southern Manitoba, including the City of Winnipeg, and is home to the seven First Nations that make up Treaty One Nations today. Associated links Treaty One Nations Treaty Texts - Treaties No. 1 and No. 2 Additions to Reserve Stay connected Join the conversation about Indigenous Peoples in Canada: X: @GCIndigenous Facebook: @GCIndigenous Instagram: @gcindigenous Facebook: @GCIndigenousHealth You can subscribe to receive our news releases and speeches via RSS feeds. For more information or to subscribe, visit SOURCE Indigenous Services Canada
Cision Canada
31 minutes ago
- Cision Canada
EV PROJECTS LIMITED ANNOUNCES INVESTMENT IN ORDINARY SHARES OF SEDIBELO RESOURCES LIMITED
ST. HELIER, Jersey, Aug. 21, 2025 /CNW/ - EV Projects Limited (" EVP") announced today that on August 18, 2025, it acquired 1,547,987,616 ordinary shares (the " Acquired Shares") in the capital of Sedibelo Resources Limited (the " Corporation") for aggregate consideration of US$5 million, or US$0.00323 per ordinary share, pursuant to a private placement (the " Private Placement"). The Acquired Shares represent approximately 17.8% of the Corporation's total issued and outstanding ordinary shares. In addition, EVP also acquired 1,547,987,616 options to purchase ordinary shares (the " Acquired Options") of the Corporation in connection with its subscription for the Acquired Shares. Each Acquired Option is exercisable to acquire one ordinary share (a " Option Share") at a price of US$0.00323 per Option Share for a period of three years from the date of issue. On a partially diluted basis, assuming all outstanding options of the Corporation are exercised in full except for the Acquired Options, EVP would hold 1,547,987,616 ordinary shares, representing approximately 9.5% of the total issued and outstanding shares. Alternatively, if only the Acquired Options are exercised in full while no other shareholders exercise their options, EVP's holdings would increase to 3,095,975,232 ordinary shares, representing approximately 30.2% of the issued and outstanding shares. If no shareholders, including EVP, exercise their options, EVP's ownership would remain at 17.8%. EVP acquired the Acquired Shares and Acquired Options for investment purposes. EVP may, from time to time, acquire additional securities, dispose of some or all of the currently held or additional securities or may continue to hold the securities of the Corporation. An early warning report relating to these transactions will be filed on the System for Electronic Document Analysis and Review + under the Corporation's profile and can be viewed at
